JRCT ID: jRCT2033200293
Registered date:13/01/2021
An extension study of JR-031 in infants with neonatal hypoxic ischemic encephalopathy (hereinafter referred to as nHIE) for which hypothermia therapy is indicated
Basic Information
Recruitment status | Complete |
---|---|
Health condition(s) or Problem(s) studied | neonatal hypoxic ischemic encephalopathy (nHIE) |
Date of first enrollment | 22/02/2021 |
Target sample size | 13 |
Countries of recruitment | |
Study type | Observational |
Intervention(s) | None |
Outcome(s)
Primary Outcome | Kyoto Scale of Psychological Development 2001 |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | > 1age old |
---|---|
Age maximum | < 2age old |
Gender | Both |
Include criteria | An infant whose parent (legal representative) provides written informed consent |
Exclude criteria | An infant who, in the opinion of the investigator or subinvestigator, is not appropriate for the study |
Related Information
Primary Sponsor | Yamamoto Tatsuyoshi |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) |
Contact
Public contact | |
Name | Tatsuyoshi Yamamoto |
Address | 11-18 Kusunoki-cho, Ashiya, Hyogo Hyogo Japan 659-0015 |
Telephone | +81-797-32-8582 |
clinical_development@jp.jcrpharm.com | |
Affiliation | JCR Pharmaceuticals Co., Ltd. |
Scientific contact | |
Name | Tatsuyoshi Yamamoto |
Address | 11-18 Kusunoki-cho, Ashiya, Hyogo Hyogo Japan 659-0015 |
Telephone | +81-797-32-8582 |
clinical_development@jp.jcrpharm.com | |
Affiliation | JCR Pharmaceuticals Co., Ltd. |